Limfoproliferativne neoplazme i adenokarcinom bubrega – Da li postoji povezanost?

  • Zorica Cvetković Department of Hematology, Clinical Hospital Center Zemun, Belgrade, Serbia
  • Nada Suvajdžić-Vuković Clinic of Hematology Clinical Center of Serbia Faculty of Medicine University of Belgrade, Belgrade
  • Bora Cvetković Department of Urology, Clinical Hospital Center Zemun, Belgrade
DOI: https://doi.org/10.2298/5760
Ključne reči: lymphoproliferative disorders||, ||limfoproliferativni poremećaji, neoplasms||, ||neoplazme, kidney noplasms||, ||bubreg, neoplazme, comorbidity||, ||komorbiditet, risk factors||, ||faktori rizika, prognosis||, ||prognoza,

Sažetak


Uvod. Epidemiološkim studijama utvrđena je značajna povezanost limfoproliferativnih neoplazmi (LPN) i adenokarcinoma bubrega (renal cell carcinoma – CRC), ali uzrok ove povezanosti nije utvrđen. Kao mogući etiološki faktori navode se: efekat primenjene citotoksične terapije, infekcije virusima, imunomodulatorni efekat tumora, genetska predispozicija i uticaj faktora spoljašnje sredine. Prikazi bolesnika. Retrospektivnom studijom obuhvaćeno je 680 bolesnika sa LPN i 570 bolesnika sa adenokarcinomom bubrega dijagnostikovanih u dve ustanove u peridu januar 1997 – decembar 2011. godine. Udruženost oboljenja utvrđena je kod pet bolesnika (3 muškarca, 2 žene) čije su demografske i kliničkopatološke karakteristike prikazane. Zaključak. Istovremeno postavljanje dijagnoze ili suviše kratak latentni period između postavljanja dijagnoze LPN i adenokarcinoma bubrega kao i odsustvo primarne citotoksične terapije govore u prilog zajedničkoj patobiologiji ovih maligniteta.

Reference

Vardiman JW, Brunning RD, Arber DA, le Beau MM. Introduction and overview of the classification of the myeloid neoplasms. In: Swerdlow SH, Campo E, Harris LN, Jaffe ES, Pileri SA, Stein H, editors. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 127−9.

Nishikubo CY, Kunkel LA, Figlin R, Belldegrun A, Rosen P, Elashoff R, et al. An association between renal cell carcinoma and lymphoid malignancies. A case series of eight patients. Cancer 1996; 78(11): 2421−6.

Liu H, Hemminki K, Sundquist J. Renal cell carcinoma as first and second primary cancer: etiological clues from the Swedish Family-Cancer Database. J Urol 2011; 185(6): 2045−9.

Ojha RP, Evans EL, Felini MJ, Singh KP, Thertulien R. The asso-ciation between renal cell carcinoma and multiple myeloma: insights from population-based data. BJU Int 2011; 108(6): 825−30.

Anderson CM, Pusztai L, Palmer JL, Cabanillas F, Ellerhorst JA. Coincident renal cell carcinoma and nonHodgkin's lymphoma: the M. D. Anderson experience and review of the literature. J Urol 1998; 159(3): 714−7.

Ohsawa M, Hashimoto M, Yasunaga Y, Shingu N, Aozasa K. Char-acteristics of non-Hodgkin's lymphoma complicated by renal cell malignancies. Oncology 1998; 55(5): 482−6.

Kunthur A, Wiernik PH, Dutcher JP. Renal parenchymal tumors and lymphoma in the same patient: case series and review of the literature. Am J Hematol 2006; 81(4): 271−80.

Badros A, Karakunnel J, Dawson N. Multiple myeloma and renal cell carcinoma possible association. Leuk Lymphoma 2007; 48(8): 1662−4.

Bhandari MS, Mazumder A, Jagannath S, Vesole DH. Association between renal cell carcinoma and plasma cell dyscrasias: a case series of six patients. Clin Lymphoma Myeloma 2008; 8(3): 188−90.

Ozturk MA, Dane F, Kaygusuz I, Asmaz O, Uzay A, Bayik M, et al. Synchronous renal cell carcinoma and multiple myeloma: report of two cases and review of the literature. J BUON 2009; 14(3): 511−4.

Serefhanoglu S, Buyukasik Y, Goker H, Akin SC, Akin S, Sayinalp N, et al. Concomitant renal cell carcinoma and lymphoid ma-lignancies: a case series of five patients and review of the litera-ture. Med Oncol 2010; 27(1): 55−8.

National Cancer Institute. Surveillance, Epidemiology and End results data. 2014. Available from: http://seer.cancer.gov/data/index:htm.

Travis LB, Curtis RE, Boice JD, Hankey BF, Fraumeni JF. Second cancers following non-Hodgkin's lymphoma. Cancer 1991; 67(7): 2002−9.

Travis LB, Curtis RE, Glimelius B, Holowaty E, Van Leeuwen FE, Lynch CF, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993; 85(23): 1932–7.

Beisland C, Talleraas O, Bakke A, Norstein J. Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int 2006; 97(4): 698−702.

Chakraborty S, Tarantolo SR, Batra SK, Hauke RJ. Incidence and prognostic significance of second primary cancers in renal cell carcinoma. Am J Clin Oncol 2013; 36(2): 132−42.

Lossos C, Ferrell A, Duncan R, Lossos IS. Association between non-Hodgkin lymphoma and renal cell carcinoma. Leuk Lymphoma 2011; 52(12): 2254−61.

Choueiri TK, Baz RC, McFadden CM, Khasawneh M, Karam MA, Kelly M, et al. An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. BJU Int 2008; 101(6): 712−5.

Rabbani F, Grimaldi G, Russo P. Multiple primary malignancies in renal cell carcinoma. J Urol 1998; 160(4): 1255−9.

Rabbani F, Reuter VE, Katz J, Russo P. Second primary malignancies associated with renal cell carcinoma: influence of histologic type. Urology 2000; 56(3): 399−403.

Cairns P. Renal cell carcinoma. Cancer Biomark 2010; 9(1−6): 461−73.

Contreras-Ibáñez JA, Díaz-Gómez L, Muriel-Cueto P. Renal synchronous carcinoma of clear cells with non-hodgkin lymphoma of phenotype b of type MALT. Actas Urol Esp 2010; 34(9): 818−9.

David AW, Indrani S, Apurva S, Sukria N, Benjamin P. Burkitt's lymphoma of the ileum with renal cell carcinoma. Can J Surg 2008; 51(4): E77−8.

Chang MY, Chen YM, Chen YC, Tian YC, Fang JT, Yang CW. Concurrent renal cell carcinoma and central nervous system lymphoma in a patient with autosomal dominant polycystic kidney disease. Med Princ Pract 2009; 18(6): 486−9.

Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos M. Clinical implications of chromosomal abnormalities in multiple myeloma. Leuk Lymphoma 2006; 47(5): 803−14.

Allory Y, Culine S, de la Taille A. Kidney cancer pathology in the new context of targeted therapy. Pathobiology 2011; 78(2): 90−8.

Burger R. Impact of interleukin-6 in hematological malignancies. Transfus Med Hemother 2013; 40(5): 336−43.

Anderson KC. Multiple Myeloma. Advances in disease biology: therapeutic implications. Semin Hematol 2001; 38(2 Suppl 3): 6−10.

Song G, Li Y, Jiang G. Role of VEGF/VEGFR in the patho-genesis of leukemias and as treatment targets (Review). Oncol Rep 2012; 28(6): 1935−44.

Polimeno M, Napolitano M, Costantini S, Portella L, Esposito A, Ca-pone F, et al. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, ep-idermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU Int 2013; 112(5): 686−96.

Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, et al. Tar-geting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 2014; 141(2): 125−39.

Vano YA, Tartour E, Fournier LS, Beuselinck B, Mejean A, Oudard S. Prognostic factors in patients with advanced renal cell carci-noma treated with VEGF-targeted agents. Expert Rev Anti-cancer Ther 2014; 14(5): 523−42.

Podar K, Anderson KC. Emerging therapies targeting tumor vas-culature in multiple myeloma and other hematologic and solid malignancies. Curr Cancer Drug Targets 2011; 11(9): 1005−24.

Morgan GJ, Davies FE, Linet M. Myeloma aetiology and epide-miology. Biomed Pharmacother 2002; 56(5): 223−34.

Lipworth L, Tarone RE, Lund L, McLaughlin JK. Epidemiologic characteristics and risk factors for renal cell cancer. Clin Epi-demiol 2009; 1: 33−43.

Objavljeno
2015/11/02
Broj časopisa
Vol. 72 Br. 8 (2015)
Rubrika
Prikaz bolesnika